<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Dendreon Corp. | Company News & Executive Profiles - DNDN | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/dendreon+corp..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Dendreon Corp.]]></description>
	<s:counts start="0" returned="10" found="89" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Dendreon's Provenge Looks Likely to Be Approved in Mid-2010]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F170813-dendreon-s-provenge-looks-likely-to-be-approved-in-mid-2010%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[VFC submits:  Shares of Dendreon DNDN traded as much as five percent higher on Monday morning after the company announced that it has re-submitted its application for the regulatory approval of Provenge, a therapeutic prostate cancer vaccine that was called 'approvable' by the FDA in 2007. According to the...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 03 Nov 2009 05:48:21 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/vfc%2527s+stock+house.html"><![CDATA[VFC's Stock House]]></category>
		<category domain="http://resources.bnet.com/topic/dendreon+corp..html"><![CDATA[Dendreon Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNDN</category>
		<category domain="tickers">DNDN</category>
	</item>
	<item>
		<title><![CDATA[Dendreon Investors Counting on FDA Approval of Provenge]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F163800-dendreon-investors-counting-on-fda-approval-of-provenge%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   Dendreon Corporation (DNDN - Analyst Report) is likely to become the first company to receive approval from the U.S. Food and Drug Administration FDA for an anti-cancer, immunotherapy based vaccine, as it released phase III IMPACT Immunotherapy for Prostrate AdenoCarcinoma Treatment trial results for its key...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 28 Sep 2009 03:01:40 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/dendreon+corp..html"><![CDATA[Dendreon Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNDN</category>
		<category domain="tickers">DNDN</category>
	</item>
	<item>
		<title><![CDATA[SEC Shouldn't Rest On Flash Trading Ban]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F162304-sec-shouldn-t-rest-on-flash-trading-ban%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Matthew Goldstein submits:  Securities regulators will often settle for the proverbial low-hanging fruit -- prosecuting easy cases that don't make a big difference in the way Wall Street operates. But it does give the appearance they're doing something. And so it is with the Securities and Exchange Commission's proposal...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Fri, 18 Sep 2009 07:44:35 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/us+market.html"><![CDATA[US Market]]></category>
		<category domain="http://resources.bnet.com/topic/matthew+goldstein.html"><![CDATA[Matthew Goldstein]]></category>
		<category domain="http://resources.bnet.com/topic/dendreon+corp..html"><![CDATA[Dendreon Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/ual+corp..html"><![CDATA[UAL Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNDN</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">UAUA</category>
		<category domain="tickers">DNDN,UAUA</category>
	</item>
	<item>
		<title><![CDATA[Dendreon: Charting the Course to Big Profits]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F142392-dendreon-charting-the-course-to-big-profits%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Jamie Moye submits: While the number of North American men being diagnosed annually with prostate cancer has seen a slight decline during the past decade, this trend will likely reverse in the coming years due to the aging of the Baby Boomers, who are just entering the demographic most susceptible...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 10 Jun 2009 03:46:58 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/jamie+moye.html"><![CDATA[Jamie Moye]]></category>
		<category domain="http://resources.bnet.com/topic/dendreon+corp..html"><![CDATA[Dendreon Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNDN</category>
		<category domain="tickers">DNDN</category>
	</item>
	<item>
		<title><![CDATA[Dendreon Laughs Last]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F138444-dendreon-laughs-last%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[The Burrill Report submits:           What a long, strange trip it&#8217;s been for Dendreon DNDN.  Three years ago, positive results from a trial of Provenge, its immune therapy drug for prostate cancer, prompted an FDA advisory panel to recommend that...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 19 May 2009 05:44:45 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/the+burrill+report.html"><![CDATA[The Burrill Report]]></category>
		<category domain="http://resources.bnet.com/topic/dendreon+corp..html"><![CDATA[Dendreon Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNDN</category>
		<category domain="tickers">DNDN</category>
	</item>
	<item>
		<title><![CDATA[Why Sales Estimates for Dendreon's Provenge Are Too Low]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F138294-why-sales-estimates-for-dendreon-s-provenge-are-too-low%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Dan Rosenblum submits: After the initial excitement caused by the Phase 3 IMPACT study of Dendreon's DNDN Provenge for the treatment of metastatic prostate cancer has begun to fade along with the stock price, it is time to consider just how big a drug Provenge can become.   ...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 18 May 2009 12:40:22 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/dan+rosenblum.html"><![CDATA[Dan Rosenblum]]></category>
		<category domain="http://resources.bnet.com/topic/dendreon+corp..html"><![CDATA[Dendreon Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNDN</category>
		<category domain="tickers">DNDN</category>
	</item>
	<item>
		<title><![CDATA[Provenge Approval: Dendreon CEO Offers Hazy Outlook]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F137395-provenge-approval-dendreon-ceo-offers-hazy-outlook%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Scibby submits: Dr Mitchell Gold is a marketing genius. With a piece of news a couple of weeks ago, he has secured his financial freedom for him and his close allies.      He has risen from a no-one to demi-god status in weeks, thanks to his...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 13 May 2009 03:37:20 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/scibby.html"><![CDATA[Scibby]]></category>
		<category domain="http://resources.bnet.com/topic/dendreon+corp..html"><![CDATA[Dendreon Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNDN</category>
		<category domain="tickers">DNDN</category>
	</item>
	<item>
		<title><![CDATA[Why Did Dendreon Execs Cash Out on Friday?]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F135250-why-did-dendreon-execs-cash-out-on-friday%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Huckman submits:  Whenever a politician, government agency or company puts out news late on a Friday, chances are it probably isn't good or it's stuff they'd like to just slip under the door. That's when they like to dump stuff that will usually get less attention over a...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 05 May 2009 12:10:41 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/mike+huckman.html"><![CDATA[Mike Huckman]]></category>
		<category domain="http://resources.bnet.com/topic/dendreon+corp..html"><![CDATA[Dendreon Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNDN</category>
		<category domain="tickers">DNDN</category>
	</item>
	<item>
		<title><![CDATA[Dendreon Investors Learn a Hard Lesson in Stop-Loss Orders]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F134278-dendreon-investors-learn-a-hard-lesson-in-stop-loss-orders%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  We now have more data on Dendreon&#8217;s DNDN results for their prostate cancer therapy Provenge, and the numbers do, in fact, look good. This isn't a cure for refractory prostate cancer, but there seems to be a real statistical improvement in survival, with side effects no...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 30 Apr 2009 06:39:15 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/dendreon+corp..html"><![CDATA[Dendreon Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNDN</category>
		<category domain="tickers">DNDN</category>
	</item>
	<item>
		<title><![CDATA[Dendreon: Bear Trap of the Year]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F134269-dendreon-bear-trap-of-the-year%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[J.C. Kommer submits:  Down 45% one day, up 95% the next.     The 45% drop happened in 5 minutes. by Jean-Claude Kommer]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 30 Apr 2009 06:03:17 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/jean-claude+kommer.html"><![CDATA[Jean-Claude Kommer]]></category>
		<category domain="http://resources.bnet.com/topic/dendreon+corp..html"><![CDATA[Dendreon Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNDN</category>
		<category domain="tickers">DNDN</category>
	</item>
</channel>
</rss>
